A Review on Assessment on The Dispensing Pattern of Drugs in The Management of Respiratory Tract Infections

A number of drugs are used to treat type 2 diabetes (T2D), a global health concern. The health of patients and adherence to therapy are at risk due to adverse drug reactions (ADR). The purpose of this study was to assess ADRs in T2D patients taking anti-diabetic drugs and to examine prescribing trends. 615 T2D individuals were included in an observational ambispective study that lasted six months. Patient demographics, comorbidities, length of illness, body mass index, prescribed drugs, and ADRs were among the information gathered. The WHO-Uppsala Monitoring Centre (WHO-UMC) criteria were used to evaluate the causal link between the drug and ADR. Microsoft Excel 365 program was used to create a descriptive summary of the data. 220 out of 615 individuals had at least one ADR. Out of 220, female patients experienced a higher percentage of ADR occurrences (37.6%) than male patients (34.4%). Biguanides were the most often given medications, followed by thiazolidinediones and dipeptidyl peptidase-4 inhibitors. Patients on metformin experienced more adverse drug reactions (ADRs), followed by those on pioglitazone, glimepiride, sitagliptin, and dapagliflozin. Based on WHO UMC causation classifications, all reported ADRs were classified as "Possible". The study underlines the importance of careful monitoring and the noteworthy incidence of ADRs in T2D patients.